CONMED Corp. 10-Q Summary: Quarter Ended March 31, 1999
Business Context and Reporting Period
This Form 10-Q covers the three-month period ended March 31, 1999, for CONMED Corporation, a leading developer and manufacturer of medical instruments and systems for surgical and other medical procedures. The company operates as a single segment, offering products such as arthroscopic devices, powered surgical instruments, and electrosurgical systems. The financial statements are unaudited.
Key Financial Metrics
| Metric | Q1 1999 | Q1 1998 |
|---|---|---|
| Net Sales | $90.9 million | $80.2 million |
| Income from Operations | $17.8 million | $11.3 million |
| Net Income | $6.3 million | $0.9 million |
| Diluted EPS (Net Income) | $0.41 | $0.06 |
| Gross Margin (Adjusted) | 52.1% | 48.4% |
| Operating Cash Flow | $6.1 million | $14.0 million |
| Total Debt (Current + Long-term) | $380.0 million | $384.9 million |
| Cash and Equivalents | $4.2 million | $13.5 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13.2% to $90.9 million, driven primarily by increased orthopaedic product sales and improved pricing from shifting distribution from Zimmer, Inc. to direct sales.
- Profitability: Net income surged to $6.3 million from $0.9 million. This improvement is largely due to the absence of a $1.6 million (net of tax) extraordinary charge in 1999 related to the write-off of deferred financing fees that occurred in Q1 1998.
- Cost Structure: Cost of sales decreased nominally to $43.5 million from $44.4 million. Excluding a one-time $3.0 million inventory write-up in 1998, the underlying cost of sales increased due to volume, but gross margin percentage improved to 52.1% from 48.4%.
- Expenses: Selling and administrative expenses rose to $26.6 million (29.2% of sales) from $21.8 million (27.1% of sales) due to costs associated with direct distribution and new product launches. R&D expenses remained relatively flat at 3.3% of sales.
- Cash Flow: Operating cash flow declined to $6.1 million from $14.0 million, negatively impacted by a $5.0 million increase in inventory and decreases in accrued liabilities, despite higher net income.
Outlook, Risks, and Management Commentary
- Liquidity: The company maintains a $100 million revolving credit facility with $62 million available as of March 31, 1999. Management believes cash from operations and available credit are sufficient for working capital and debt service.
- Debt Obligations: The company holds $130 million in subordinated notes maturing in 2008 at 9.0% interest and term loans totaling $211.1 million. Interest rate swaps are in place to fix rates on $100 million of floating debt.
- Year 2000 Compliance: Remediation of IT and non-IT systems is on schedule for completion by June 30, 1999. Costs are not expected to be material, though risks remain regarding third-party failures.
- Foreign Operations: The company is monitoring the Euro Conversion impact on European operations but does not anticipate material costs or competitive disadvantages.
- Forward-Looking Statements: Results are subject to risks including economic conditions, competition, technology changes, and the integration of acquisitions.
Investor Verification Checklist
- Verify the sustainability of the gross margin improvement (52.1%) following the shift to direct distribution.
- Confirm the timeline and cost implications of the Year 2000 remediation program completion by June 30, 1999.
- Monitor inventory levels, which increased by $4.4 million in the quarter, and their impact on future working capital.
- Review the terms of the $100 million revolving credit facility and the company's compliance with financial covenants.
- Assess the impact of the $17.5 million arthroscopy product line acquisition on future revenue streams.